Skip to content

Improving heart failure detection

Heart failure is difficult to spot, but new advances in technology can improve detection.

75% of individuals are missed a heart failure diagnosis

The clinical diagnosis of heart failure is known to be difficult, especially in the early stages the disease. Most patients are only diagnosed after an emergency hospital admission.

50% of individuals over age 45 have Stage B heart failure

Often referred to as silent heart failure, these patients have no signs or symptoms, adding to the complexity of diagnosis. If untreated they progress to Stage C and a 5-fold increase in mortality risk. [1]

We need to address this crisis fast

We know more than we did 10 years ago

Heart failure has historically been diagnosed by evaluating a patient’s ejection fraction (EF) – or how effectively the heart is pushing blood to the body.

However, 50% of heart failure patients have what is referred to as heart failure with preserved ejection fraction (HFpEF). [3]

But current clinical practice makes HFpEF a challenge to diagnose and often, providers don’t look deeper than the standard ejection fraction measure.  

This contributes to missed heart failure diagnosis, and treatment that is often too late.

Time to focus on HFpEF

HFpEF accounts for half of all heart failure

HFpEF accounts for half of the 64 million cases of heart failure, and cases are estimated to double by 2030.

Diagnosing HFpEF relies on time-consuming analysis and invasive testing such as catheterization. 

The rates of misdiagnosis using these clinical algorithms can be up to 75% in some care settings, delaying therapy and contributing to a high number of hospitalizations and poor mortality rate.

We need to catch and intervene heart failure – including HFpEF – earlier and with precision.

And now, finally, we can.

Precision heart failure detection

Ultromics combines echocardiography - the most common and cost effective cardiac imaging modality - with AI-derived insights that go beyond what the human eye can see.

This means improved outcomes, fewer unnecessary invasive procedures, and reduced costs through precision heart failure detection.


Why precision matters

New treatments make it more important than ever to quickly and accurately diagnose heart failure

Sodium-glucose cotransporter 2 inhibitors
(SGLT2i's) and other new drug therapies have been shown to improve both HFrEF and HFpEF patient outcomes. [6]

These SGLT2i's can reduce death and hospitalizations by 20-40% [5]

Effective and fast diagnoses lead to earlier treatment with these new classes of drugs and, combined with effective patient management, can have a significant impact.

Echocardiography remains the safest and most accessible option


Echocardiography is already the most common means of diagnosing heart failure, with over 30 million exams being performed each year. [7]

Echocardiography is low-cost, accessible, portable, and safe for patients, and with AI automating insights, it removes manual time, subjectivity and variability in calculating analysis, and provides accurate heart failure diagnostics to any care setting.

Improving precision can benefit individuals

AI-driven predictive analytics in healthcare helps to reduce patient admissions.

Improving precision can help reduce the significant cost for individuals


The annual median medical costs for heart failure care per patient.2



The number of direct heart failure costs attributed to inpatient stays.


> 3 million

The number of admissions of patients over 65 years of age. As the population of this age group increases, so too will readmissions. 3
> 3 million

#1 driver

The number one cause of Medicare costs relative to any other diagnosis.
#1 driver


  1. Sanders-van Wijk S, Aizpurua AB, Brunner-La Rocca HP, et al. The HFA-PEFF and H2FPEF scores largely disagree in classifying patients with suspected heart failure with preserved ejection fraction. European Journal of Heart Failure. 2021;23:838-840
  2. Urbich M. Globe G, Pantiri K, et al. A Systematic Review of Medical Costs Associated with Heart Failure in the USA (2014-2020). Pharmacoeconomics. 2020;38:1219-1236
  3. Shah SJ, Borlaug BA, Kitzman DW, et al. Research Priorities for Heart Failure With Preserved Ejection Fraction: National Heart, Lung, and Blood Institute Working Group Summary. Circulation. 2020;141:1001-1026.
  4. Nichols GA, et al. J Am Coll Cardiol. 2022;79: (9 Supplement):283
  5. Cunningham JW, Vaduganathan M, Claggett BL, et al. Dapagliflozin in Patients Recently Hospitalized With Heart Failure and Mildly Reduced or Preserved Ejection Fraction. Journal of the American College of Cardiology. 2022;80:1302–1310
  6. Heidenreich PA, Bozkurt B, Aguilar D, et al. 2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. Journal of the American College of Cardiology. 2022;79:263-421
  7. Deloittes Proprietary Data

Curious about upcoming research and innovation?

Sign up to hear about the latest news.